A Study of Phase Ib/II to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis
Latest Information Update: 05 Sep 2022
At a glance
- Drugs QY 201 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors E-nitiate Biopharmaceuticals
Most Recent Events
- 05 Sep 2022 New trial record